The Quantellect read.As of Nov 19, 2026, 12 active firms cover Option Care Health Inc: 2 rate it Buy or better, 10 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $22.00 to $485.00 (about 22.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $70.92 sits 124% above the current $31.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.45 next quarter toward $2.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Neutral
Strong Buy00%
Buy217%
Neutral1083%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$70.92
+123.6% upside
Average target across 11 active firms as of Nov 19, 2026 vs $31.72 current
Highest Target$485.00
Average Target$70.92
Lowest Target$22.00
Detailed analyst forecasts for OPCH
Showing 1–12 of 12 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 2 of 12 active firms rate OPCH a Buy (10 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OPCH EPS & revenue forecast
EPS · NEXT QUARTER
$0.45
Range $0.42 – $0.50 · 8 analysts · +12% YoY
Next period, 8 analysts expect Option Care Health Inc to earn $0.45 a share (range $0.42 – $0.50), versus $0.40 a year earlier. Full-year consensus is $1.89, growing to $2.08 the year after.
REVENUE · NEXT QUARTER
$1.4B
Range $1.4B – $1.5B · 8 analysts · +7% YoY
Revenue is expected to reach $1.4B (range $1.4B – $1.5B), +7.1% year-over-year. Full-year consensus is $5.8B, rising to $6.1B next year.
Top analysts covering Option Care Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OPCH.
#1
Erin Wright
Morgan Stanley · Rank #81
Buy
$28.00-11.7% to target
Overall win rate
55%
+ Follow
#2
DM
David Macdonald
Truist Securities · Rank #111
Buy
No targeton OPCH
Overall win rate
50%
+ Follow
#3
Brian Tanquilut
Jefferies · Rank #280
Neutral
$32.05+1.0% to target
Overall win rate
46%
+ Follow
#4
AR
A.J. Rice
UBS · Rank #365
Neutral
$32.05+1.0% to target
Overall win rate
35%
+ Follow
#5
Michael Petusky
Barrington Research · Rank #452
Neutral
No targeton OPCH
Overall win rate
32%
+ Follow
OPCH stock forecast FAQ
What is OPCH's average 12-month price target?+
The 11 active firms with a live target average $70.92 for Option Care Health Inc over the next 12 months, ranging from a $485.00 high to a $22.00 low, as of Nov 19, 2026.
Is OPCH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 12 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 10 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OPCH?+
The Street-high target is $485.00 (Morgan Stanley), and the Street-low is $22.00 (Goldman Sachs). The average of all 11 active-firm targets is $70.92.
How many active Wall Street firms cover OPCH?+
12 active firms have a recognized rating on Option Care Health Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OPCH?+
Among analysts who currently cover OPCH, Erin Wright of Morgan Stanley has the strongest overall Quantellect track record (Rank #81). Their current call is Buy with a $28.00 target.
What is Option Care Health Inc's projected EPS for next quarter?+
The consensus estimate is $0.45 per share (range $0.42 – $0.50) across 8 analysts. Full-year EPS is projected at $1.89, rising to $2.08 the following year.
How much revenue is Option Care Health Inc expected to report next quarter?+
Consensus revenue is $1.4B (range $1.4B – $1.5B). Full-year revenue is projected at $5.8B, growing to $6.1B next year.
Have analysts been upgrading or downgrading OPCH lately?+
As of Nov 19, 2026, 2 of 12 active firms rate OPCH a Buy (10 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OPCH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.